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Elective Percutaneous Coronary Intervention (PCI) Page 3 of 34 Reproduction without authorization from Blue Shield of California is prohibited According to Singh et al other factors may influence the choice of revascularization procedures, and may be considered in appropriateness decision-making. In general, CABG is preferred in cases in which significant blockage is present in several sites in the same artery, where SYNTAX scores (see below for definition) are high, and in patients in whom there is a history of diabetes, excessive bleeding, aspirin (or clopidogrel) allergy, or left ventricular systolic dysfunction (with an ejection fraction of less than 45% or documented diastolic dysfunction). On the other hand, in cases of high stroke risk, dementia, previous CABG, or significant pulmonary disease, PCI may be preferable. 6 
Canadian Cardiovascular Society Grading of Angina Pectoris
The reference standard used for the grading of angina severity is the Canadian Cardiovascular Society system:
• Grade I: Ordinary physical activity does not cause angina, such as walking and climbing stairs. Angina with strenuous or rapid or prolonged exertion at work or recreation. • Grade II: Slight limitation of ordinary activity. Walking or climbing stairs rapidly, walking uphill, walking or stair climbing after meals, or in cold, or in wind, or under emotional stress, or only during the few hours after awakening. Walking more than two blocks on the level and climbing more than one flight of ordinary stairs at a normal pace and in normal conditions. • Grade III: Marked limitation of ordinary physical activity. Walking one or two blocks on the level and climbing one flight of stairs in normal conditions and at normal pace. • Grade IV: Inability to carry on any physical activity without discomfort, anginal syndrome may be present at rest. home
Unstable angina is considered to be present in patients with ischemic symptoms suggestive of acute coronary syndrome (ACS) and no elevation in troponin, with or without electrocardiogram (ECG) changes indicative of ischemia (e.g., ST segment depression or transient elevation or new T wave inversion). Three different presentations of unstable angina exist:
• Exertional angina of new onset (even if relieved with rest and requiring a consistent amount of exertion to produce symptoms, angina is considered unstable when it first occurs) • Exertional angina that was previously stable and now occurs with less physical exertion • Anginal symptoms at rest In unstable angina, the cardiac enzymes remain normal or are only very minimally elevated.
Intensity of Anti-Anginal Therapy
Maximal anti-anginal therapy (referred to as "Optimal Medical Therapy" elsewhere in this document) consists of the continuous use of drugs from two of four anti-anginal classes (beta blockers, calcium channel blockers, sodium channel blockers, nitrates) titrated to maximal efficacy and/or tolerance. Minimal therapy is use of one class of anti-anginal drugs. An assumption is made that agents to treat hypertension and hyperlipidemia, as well as antiplatelet agents, are in use as indicated and also titrated to maximally efficacious and/or tolerated effect. home
Coronary Anatomical Findings on Diagnostic Coronary Angiography
Typically, elective coronary revascularization procedures would have been preceded by diagnostic coronary angiography, however, significant culprit lesions may be detected on the diagnostic study that should be immediately addressed by PCI to avoid further morbidity. In such circumstances, the request for the PCI procedure may be submitted retroactively, but all criteria for "appropriate" intervention must be met.
For the purpose of the clinical scenarios listed in this policy, a "significant" coronary stenosis for an epicardial (non-left main) artery is equal to or greater than 70% luminal diameter narrowing BSC6.02
Elective Percutaneous Coronary Intervention (PCI) Page 4 of 34 Reproduction without authorization from Blue Shield of California is prohibited by visual assessment, as assessed in the "worst view" projection. For a left main stenosis, greater or equal to 50% narrowing is required.
If questions of the degree of stenosis by visual estimation are encountered, fractional flow reserve (FFR) across the stenosis may be used as an indicator of stenosis severity. With an FFR of 1.0 is widely accepted as normal, an FFR lower than 0.75-0.80 is generally considered to be associated with significant stenosis/myocardial ischemia. Intravascular plaque morphology resulting in significant stenosis may also be determined by intravascular ultrasound (IVUS). home
Appropriate Use Criteria for Coronary Revascularization
The table below is taken directly from the "ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria (AUC) for Coronary Revascularization in patients with Stable Ischemic Heart Disease (SIHD)" and is to be used for the determination of "appropriate use" in this policy. In the "Appropriate Use Score" columns, Roman numerals I, II, III and IV refer to Canadian Cardiovascular Society angina scores. 1 (Link to Appropriate Use Criteria for Coronary Revascularization abbreviations) 
The number in parentheses next to the rating reflects the median score for that indication. A indicates appropriate; AA = antianginal; BB = beta blockers; CABG = coronary artery bypass graft; LMCA = left main coronary artery; M = may be appropriate; PCI = percutaneous coronary intervention; R = rarely appropriate; and SYNTAX = Synergy between PCI with Taxus and Cardiac Surgery trial.
home The number in parentheses next to the rating reflects the median score for that indication. *iFR measurements with appropriate normal ranges may be substituted for FFR. A indicates appropriate; AA = antianginal; BB = beta blockers; CABG = coronary artery bypass graft; FFR = fractional flow reserve; iFR = instant wave-free ratio; IMA = internal mammary artery; LAD = left anterior descending coronary artery; LCX = left circumflex artery; M = may be appropriate; PCI = percutaneous coronary intervention; and R = rarely appropriate. home 41. ■ Intermediate-or high-risk findings on noninvasive testing A (7) A (7) A (7) A (7) A (7) A (7) A (8) A (8) The number in parentheses next to the rating reflects the median score for that indication. *iFR measurements with appropriate normal ranges may be substituted for FFR. A indicates appropriate; AA = antianginal; BB = beta blockers; CABG = coronary artery bypass graft; FFR = fractional flow reserve; iFR = instant wave-free ratio; IMA = internal mammary artery; LAD = left anterior descending coronary artery; LCX = left circumflex artery; M = may be appropriate; PCI = percutaneous coronary intervention; and R = rarely appropriate.
home 
The number in parentheses next to the rating reflects the median score for that indication. *iFR measurements with appropriate normal ranges may be substituted for FFR. A indicates appropriate; AA = antianginal; BB, beta blockers; CABG = coronary artery bypass graft; CAD = coronary artery disease; LAD = left anterior descending coronary artery; M = may be appropriate; PCI = percutaneous coronary intervention; and R = rarely appropriate; SYNTAX = Synergy between PCI with Taxus and Cardiac Surgery trial; and TAVR, transcatheter aortic valve replacement.
home
Syntax Scores
The SYNTAX Score is based on the SYNTAX (Synergy between PCI with TAXUS drug-eluting stent and Cardiac Surgery) trial, which was designed to compare revascularization with either CABG or PCI using paclitaxel-eluting stents for three-vessel disease or left main disease (either isolated left main disease or left main disease with one-, two-, or three-vessel disease involving other arteries). Based on review of coronary angiographic studies, the SYNTAX score considers 11 measures of coronary lesion complexity, including location of lesion, coronary arterial system BSC6.02
Elective Percutaneous Coronary Intervention (PCI) Page 11 of 34 Reproduction without authorization from Blue Shield of California is prohibited dominance, length of lesions, presence of heavy calcification, thrombus, total occlusion or diffuse disease, number of diseased segments, vessel tortuosity, and location at a bifurcation, trifurcation or aorto-ostial locus. The SYNTAX trial results indicated that, for more severe CAD (SYNTAX scores greater than 22 for three-vessel or left main coronary disease), CABG offered a survival advantage over PCI, and it reduced the need for a repeat intervention and overall adverse cardiovascular events up to 4 years after revascularization.
Coding
The following list of CPT and HCPCS codes may be used for different types of coronary revascularization utilizing percutaneous coronary intervention, but this list of codes may not be all inclusive:
CPT
• 92920: Percutaneous transluminal coronary angioplasty; single major coronary artery or branch • 92921: Percutaneous transluminal coronary angioplasty; each additional branch of a major coronary artery (List separately in addition to code for primary procedure) • 92924: Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; single major coronary artery or branch • 92925: Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure) • 92928: Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch • 92929: Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure) • 92933: Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch • 92934: Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure) • 92937: Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel • 92938: Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (List separately in addition to code for primary procedure) • 92941: Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel • 92943: Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; single vessel • 92944: Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (List separately in addition to code for primary procedure) • 92978: Endoluminal imaging of coronary vessel or graft using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report; initial vessel (List separately in addition to code for primary procedure)
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Elective Percutaneous Coronary Intervention (PCI) Page 12 of 34 Reproduction without authorization from Blue Shield of California is prohibited • 92979: Endoluminal imaging of coronary vessel or graft using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report; each additional vessel (List separately in addition to code for primary procedure)
HCPCS
• C9600: Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch • C9601: Percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure) • C9602: Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch • C9603: Percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure) • C9604: Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel • C9605: Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (list separately in addition to code for primary procedure) • C9607: Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drugeluting intracoronary stent, atherectomy and angioplasty; single vessel • C9608: Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drugeluting intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (list separately in addition to code for primary procedure)
Description
Percutaneous coronary interventions (PCI) is a non-surgical procedure used to treat narrowing (stenosis) of the coronary arteries of the heart found in coronary artery disease. After accessing the blood stream through the femoral or radial artery, the procedure uses coronary catheterization to visualize the blood vessels on X-ray imaging, which allows an interventional cardiologist to perform a coronary angioplasty, using a balloon catheter in which a deflated balloon is advanced into the obstructed artery and inflated to relieve the narrowing, performed with or without coronary stent implantation.
Related Policies • Cardiac Applications of Positron Emission Tomography Scanning • Cardiac Rehabilitation in the Outpatient Setting

Benefit Application
Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the BSC6.02
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Reproduction without authorization from Blue Shield of California is prohibited time of service to determine coverage or non-coverage of these services as it applies to an individual member. Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.
Regulatory Status
Percutaneous coronary interventions (PCI) are surgical procedures, therefore are not regulated by the U.S. Food and Drug Administration (FDA).
Rationale Background
The medical necessity criteria outlined in this document govern the appropriate use of nonemergent coronary revascularizations in general, but focus on non-emergent percutaneous coronary interventions (PCI) in particular.
Percutaneous coronary interventions (PCI) are non-surgical procedures performed using vascular access through skin which restores patency of diseased coronary arteries, performed with or without coronary stent implantation. For the sake of this policy, this includes coronary atherectomy for the treatment of coronary artery disease (CAD). Elective surgical revascularization procedures, (e.g., coronary artery bypass grafting [CABG] procedures), if reviewed, must meet these elective coronary revascularization criteria, and also meet appropriateness criteria for use of the surgical approach (see Policy Guidelines section).
This medical policy is not intended to address PCI for acute coronary syndrome (ACS).
Acute indications for PCI are defined as those performed in the setting of an acute coronary syndrome, including all myocardial infarctions (ST-segment elevation and non-ST-segment elevation), as well as unstable angina (see Policy Guidelines section). 7 Findings from studies comparing PCI with coronary bypass grafting (CABG) suggest that in most patients with acute CAD with multi-vessel disease or isolated proximal left anterior stenosis amenable to either treatment, CABG led to a significantly lower long-term incidence of ischemic events and the need for repeat interventions. CABG is recommended for patients with more severe disease involving large areas of the myocardium supplied by occluded vessels or significant left main coronary artery disease.
Unexpected PCI in patients with non-acute, stable CAD, being performed immediately during or following the diagnostic coronary angiography ("ad-hoc PCI"), will be retrospectively reviewed post-service. Prior authorization is not required in these cases; however, payment will only be authorized if the medical necessity criteria below, including completion of the patient surveys (CollaboRATE and Blue Shield of California CAD decision aids) and Blue Shield of California Elective PCI Prior Authorization Request Form checklist with ACC appropriate use criteria rating, are met. It is recommended that the surveys be administered to the patient and the Blue Shield of California Elective PCI Prior Authorization Request Form checklist criteria be met prior to the diagnostic coronary angiography. Prior authorization is not required if a diagnostic coronary angiogram, or CTA with FFR, has not been performed. 
Literature Review Shared Decision Making (SDM)
Shared decision making (SDM) is promoted as an ideal model to incorporate in the treatment plan between patient and physician. This is based on the premise that the best medical decision for an individual patient incorporates the patient's preferences and values through the process of information sharing and planning. This idea involves at least two participants-the clinician and the patient. [9] [10] [11] [12] [13] [14] It represents the optimal physician-patient communication. Patients most likely to perceive their physicians as providing excellent care are those experiencing their preferred decision-making style with their primary physicians. 15, 16 Studies show that patient satisfaction, medication compliance, and health outcomes are improved by shared decision making. [17] [18] [19] On July 19, 2015, the first joint International Shared Decision-Making/International Society for Evidence-Based Health Care (ISDM/ISEHC) Conference met in Sydney, Australia with over 300 people from around the globe to share knowledge and inspire action to improve the entire health care experience. Highlights of this meeting included:
• "Informed consent" is gaining importance connected with the use of the SDM, which includes a collaborative conversation around the patient's informed preferences and the best available scientific evidence. • Aligned incentives are necessary to maximize SDM, but not necessarily monetary incentives. • Increasing in interest and gaining support is the inclusion of family engagement in the decision-making process with the patient/family/care team (called a triad) rather than the patient/care team (called a dyad). The discussion was how to make this a reality, as it has long been felt the family needed to be part of the SDM, but not easily implemented. • Development of learning programs/greater communication skills for medical students was repeatedly discussed, looking for ways to include training for these as learned skills to build conversations around patient preferences and evidence-based scientific medicine/practice. 20 Use of decision aids can promote shared decision making, and may improve patients understanding and enable them to make decisions that are fully informed and consistent with their preferences, values and goals. Development of a decision aid (Blue Shield of California "Blue Shield of California CAD" decision aid) to promote shared decision making between clinicians and patients regarding the choice of PCI+ optimal medical therapy (OMT) vs. OMT for treatment of stable CAD. The selection of PCI+OMT vs. OMT alone for stable CAD represents a preference-sensitive decision where comparable, alternative treatments exist. The decision aid is intended for use following stress testing and upstream from diagnostic angiography; if diagnostic angiography is performed, the minority of patients in whom a choice of surgery is then relevant would no longer utilize the decision aid. The resulting decision aid is intended to be nondirective, encouraging clinicians to create a conversation with patients using their own communication styles, while simultaneously ensuring that key information is conveyed and that patient preferences are elicited. [21] [22] [23] [24] [25] home
Optimal antianginal medical therapy is defined as the use of at least 2 classes of therapies to reduce anginal symptoms. ACC/AHA guidelines suggest that beta-blockers should be considered as initial therapy for chronic stable angina. Current practice guidelines indicate lowrisk patients with chronic stable angina should be treated initially with optimal medical therapy (OMT) and lifestyle modification. [26] [27] [28] [29] [30] [31] Current guidelines for the management of stable angina emphasize risk factor modification, namely smoking cessation, exercise, diabetes mellitus management, lipid lowering, antianginal,
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CollaboRATE
Patient-centered health care is a central component of current health policy agendas. Shared decision making (SDM) is considered to be the pinnacle of patient engagement and methods to promote this are becoming commonplace. However, the measurement of SDM continues to prove challenging. Reviews have highlighted the need for a patient-reported measure of SDM that is practical, valid, and reliable to assist implementation efforts. In consultation with patients, CollaboRATE was developed, a 3-item measure of the SDM process. 28 Barr et al (2014) completed a study identifying the need for scalable patient-reported measure of the SDM process. In the current project, the study assessed the psychometric properties of CollaboRATE. A representative sample of the US population was recruited online and was randomly allocated to view 1 of 6 simulated doctor-patient encounters in January 2013. Three dimensions of SDM were manipulated in the encounters: (1) explanation of the health issue, (2) elicitation of patient preferences, and (3) The key finding of this study is that developing a brief patient-reported measure of shared decision making requires a move away from terms such as 'decisions', 'options' and 'preferences'. Although technically correct, these terms act as barriers. They are often unfamiliar, and they also implicitly assume that patients are willing to take active roles in decision making; whereas patients are often unaware that decisions are required, or have taken place, never mind feel that they could or should have participated in them. The outcome of this study concluded that these methods have allowed the development of a brief, patient-reported measure of shared decision making that is highly accessible to intended users. 33 The principles of shared decision making are well documented but there is a lack of guidance about how to accomplish the approach in routine clinical practice. The aim is to translate existing conceptual descriptions into a three-step model that is practical, easy to remember, and can act as a guide to skill development. Achieving shared decision making depends on building a good relationship in the clinical encounter so that information is shared and patients are supported to deliberate and express their preferences and views during the decision making process. To accomplish these tasks, a model was proposed of how to do shared decision BSC6.02
Elective Percutaneous Coronary Intervention (PCI) Page 16 of 34 Reproduction without authorization from Blue Shield of California is prohibited making that is based on choice, option and decision talk. The model has three steps: a) introducing choice, b) describing options, often by integrating the use of patient decision support, and c) helping patients explore preferences and make decisions. This model rests on supporting a process of deliberation, and on understanding that decisions should be influenced by exploring and respecting "what matters most" to patients as individuals, and that this exploration in turn depends on them developing informed preferences. 32 o If the corresponding "appropriate use" rated level is 7 -9 ("appropriate use"), (the cardiologist must document the score and indication in the medical records) o If the corresponding "appropriate use" score is 4 -7 ("may be appropriate") or 1 -3 ("rarely appropriate"), the cardiologist must also include a brief narrative describing the clinical scenario(s) justifying the revascularization procedure. Clinical risk factors which may support the procedure include one or more of the following:  Unusual location of obstruction(s), unusual coronary anatomy, or unusual flow dynamics noted by the cardiologist  Intercurrent cardiac disease (e.g., congestive heart failure, myocardial disease, arrhythmia, valvular disease)  Current or recent smoking history (within one year)  Cardiologist documentation of difficult-to-control uncontrolled hypertension on maximal therapy or uncontrolled dyslipidemia on maximal therapy  Diabetes mellitus with a first or second degree relative with premature coronary artery disease (i.e., age less than 65, MI or coronary intervention)  Strong family history of coronary artery disease  Prior PCI or CABG procedure 
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Coding
This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy. Inclusion or exclusion of codes does not constitute or imply member coverage or provider reimbursement.
MN/NMN
The following services may be considered medically necessary when policy criteria are met. Services may be considered not medically necessary when policy criteria are not met. 
Definitions of Decision Determinations
Medically Necessary: A treatment, procedure, or drug is medically necessary only when it has been established as safe and effective for the particular symptoms or diagnosis, is not investigational or experimental, is not being provided primarily for the convenience of the patient or the provider, and is provided at the most appropriate level to treat the condition.
Investigational/Experimental: A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.
Split Evaluation: Blue Shield of California/Blue Shield of California Life & Health Insurance
Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.
Prior Authorization Requirements (as applicable to your plan)
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